ISPOR 2023: insight from Avalere’s expert presentations
At ISPOR Boston 2023, our colleagues at Avalere, part of Fishawack Health, led two live presentations. To read their insights from those presentations, including on the impact of the Inflation Reduction Act on evidence strategy, follow the link below.
ISPOR 2023 drew thousands of leading US and global healthcare researchers and decision-makers to Boston. Avalere was at the forefront, with eight experts in attendance to share insights and analysis about the future of evidence strategy following the historic Inflation Reduction Act (IRA).
The agenda was packed with insightful sessions, panels, and posters, including Avalere’s presentations on the implications of the IRA for evidence strategy and a poster describing the first phase of a novel approach to capturing person-centered disease impacts.
Visit Avalere’s website to read their insights:
- The Day After Tomorrow: Evidence, Value, and Market Access After the IRA
- IRA Negotiation: Closer to Government Price Setting or Traditional Health Technology Assessment
- Does Disease Impact Go Beyond the Healthcare System? Lessons from Generalized Myasthenia Gravis 360°
- Industry Call to Action: Rethink Evidence Strategy to Translate Insights into Implementation
Avalere and PRMA Consulting are part of Fishawack Health
In a rapidly evolving environment where stakeholders are becoming more evidence hungry and value aware, we provide best-in-class, data-driven solutions to complex healthcare challenges.
Our Policy, Access, Value, and Evidence consultancy delivers policy, market access, and HEOR solutions for global, regional, and local stakeholders in the US, Europe, Asia-Pacific, and Latin America.
As part of Fishawack Health, we are empowered by data, innovative digital applications, and experienced-based insights that accelerate time to patient access to your assets. We partner with clients who span the healthcare continuum – including the top 25 biopharma and life sciences companies, leading health plans, top healthcare providers, and healthcare investors.
Please get in touch for a confidential conversation about your policy, access, value, and evidence needs.